MEZZADRI, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 1.244
AS - Asia 1.177
EU - Europa 763
SA - Sud America 212
Continente sconosciuto - Info sul continente non disponibili 66
AF - Africa 30
OC - Oceania 1
Totale 3.493
Nazione #
US - Stati Uniti d'America 1.188
IT - Italia 454
SG - Singapore 364
VN - Vietnam 283
CN - Cina 162
BR - Brasile 152
HK - Hong Kong 124
RU - Federazione Russa 60
IN - India 48
BD - Bangladesh 46
FR - Francia 40
DE - Germania 39
GB - Regno Unito 33
KR - Corea 28
NL - Olanda 28
SE - Svezia 28
AR - Argentina 25
CA - Canada 25
ID - Indonesia 24
FI - Finlandia 20
AE - Emirati Arabi Uniti 14
MX - Messico 13
ES - Italia 12
JP - Giappone 11
TR - Turchia 11
AT - Austria 10
IQ - Iraq 10
EC - Ecuador 9
PL - Polonia 9
PH - Filippine 8
ZA - Sudafrica 8
CL - Cile 7
CO - Colombia 7
MA - Marocco 6
CH - Svizzera 5
IE - Irlanda 5
NP - Nepal 5
OM - Oman 5
PK - Pakistan 5
PY - Paraguay 5
CR - Costa Rica 4
JO - Giordania 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
UA - Ucraina 4
UY - Uruguay 4
AL - Albania 3
EG - Egitto 3
GR - Grecia 3
LT - Lituania 3
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MY - Malesia 2
NG - Nigeria 2
PE - Perù 2
PT - Portogallo 2
TN - Tunisia 2
TZ - Tanzania 2
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
FJ - Figi 1
GE - Georgia 1
GT - Guatemala 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
MU - Mauritius 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SC - Seychelles 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UG - Uganda 1
UZ - Uzbekistan 1
VC - Saint Vincent e Grenadine 1
VI - Stati Uniti Isole Vergini 1
Totale 3.427
Città #
San Jose 201
Singapore 164
Dallas 158
Ashburn 130
Hong Kong 112
Milan 106
Ho Chi Minh City 79
Hanoi 69
Hefei 57
Los Angeles 52
Council Bluffs 46
Rome 38
New York 31
Seoul 27
Beijing 25
Buffalo 21
Chicago 21
Columbus 21
Munich 19
Santa Clara 19
Phoenix 18
Da Nang 16
Jakarta 14
Lauterbourg 14
São Paulo 13
Palermo 12
Frankfurt am Main 11
Hải Dương 11
Tokyo 11
Boardman 10
Kolkata 10
Moscow 10
Al Ain City 9
Atlanta 9
Biên Hòa 9
Haiphong 9
Turku 9
Chennai 8
Orem 8
Amsterdam 7
Hyderabad 7
Lappeenranta 7
Montreal 7
Newark 7
Padova 7
Seregno 7
Turin 7
Vienna 7
Warsaw 7
Denver 6
Florence 6
Houston 6
Johannesburg 6
Kent 6
London 6
Naples 6
Paris 6
Perugia 6
Philadelphia 6
The Dalles 6
Bollate 5
Bologna 5
Brooklyn 5
Bến Tre 5
Catania 5
Figino 5
Madrid 5
Milwaukee 5
Poplar 5
Princeton 5
Quito 5
Stockholm 5
Thái Bình 5
Baghdad 4
Bari 4
Bengaluru 4
Brasília 4
Ha Long 4
Montevideo 4
Monza 4
Quận Bình Thạnh 4
Rio de Janeiro 4
San Francisco 4
Santiago 4
Toronto 4
Trento 4
Washington 4
Anchorage 3
Asunción 3
Athens 3
Bogotá 3
Brescia 3
Campinas 3
Curitiba 3
Dublin 3
Fes 3
Gradara 3
Kathmandu 3
Lecce 3
Medellín 3
Totale 1.903
Nome #
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 337
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 317
Ceftazidime-avibactam plus aztreonam versus cefiderocol in the treatment of infections caused by Metallo-β lactamase-Producing Microorganisms: real-word data from the Italian cohort SUSANA 290
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections 263
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 240
Symptomatic neurocognitive impairmentassociated to CNS viral escape in an HIV-1 infected patient: a case report. 232
Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics) 227
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 226
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study) 205
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome 181
Comparison of meropenem-vaborbactam vs ceftazidime-avibactam in the treatment of KPC producing Klebsiella pneumoniae infections 181
Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series 166
Aspergillus Endocarditis: A Rare but Serious Complication During Treatment With Ibrutinib 155
Impact of cefiderocol therapy on patient survival across different multidrugresistant Gram-negative bacilli infections. 133
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV 96
Potential for replacing protease inhibitor with doravirine in cART-experienced subjects successfully treated with darunavir-cobicistat plus dolutegravir dual regimen 86
Clinical characteristics and treatment patterns of carbapenem-resistant bloodstream infections in a multi-centre Italian cohort. 42
Imported case of avian influenza A(H9N2) virus infection in a patient with miliary tuberculosis, Italy, March 2026 38
Reasons for discontinuation of single-tablet regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) in the era of 2nd-generation INSTIs 37
When Faster Diagnosis Is Not Enough: Bringing Diagnostic Stewardship into Antimicrobial Stewardship 25
Cefiderocol therapy in multidrug-resistant Gram-negative infections: analysis from the SUSANA cohort 16
Totale 3.493
Categoria #
all - tutte 9.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.027


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202326 0 0 0 0 0 0 0 0 5 5 6 10
2023/2024144 8 7 22 5 7 7 8 7 14 38 11 10
2024/2025775 14 40 27 8 29 31 41 17 34 90 123 321
2025/20262.074 180 139 269 230 206 80 300 74 105 203 117 171
2026/2027474 142 111 221 0 0 0 0 0 0 0 0 0
Totale 3.493